Mosaicism for trisomy 21 in a patient with young-onset dementia: A case report and brief literature review

Archives of Neurology

Volumn 65, Issue 3, 2008, Pages 412-415

  Ringman, John M ^a   Rao, P Nagesh ^a,b   Lu, Po H ^a   Cederbaum, Stephen ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DONEPEZIL; MIRTAZAPINE;

ADULT; ALZHEIMER DISEASE; ANAMNESIS; ARTICLE; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTELLIGENCE QUOTIENT; INTERPHASE; MALE; MOSAICISM; ONSET AGE; PERCEPTION DEAFNESS; PERIPHERAL LYMPHOCYTE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TRISOMY 21;

ALZHEIMER DISEASE; DOWN SYNDROME; HUMANS; MALE; MIDDLE AGED; MOSAICISM;

EID: 40849113052     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.3.412     Document Type: Article

References (30)

1. Gilbert EF, Opitz JM. Developmental and other pathologic changes in syndromes caused by chromosome abnormalities. Perspect Pediatr Pathol. 1982;7:1-63.
2. Richards BW. Mosaic mongolism. J Ment Defic Res. 1969;13(1):66-83.
3. Kohn G, Taysi K, Atkins TE, Mellman WJ. Mosaic mongolism, I: clinical correlations. J Pediatr. 1970;76(6):874-879.
4. Verresen H, Vandenberghe H, Creemers J. Mosaic trisomy in phenotypically normal mother of mongol. Lancet. 1964;1:526-527.
5. Mann D. Down's syndrome and Alzheimer's disease. In: Esiri M, Lee VM-Y, Trojanowski JQ, eds. The Neuropathology of Dementia. Cambridge, England: Cambridge University Press; 2004:207-226.
6. Oliver C, Crayton L, Holland A, Hall S, Bradbury J. A four year prospective study of age-related cognitive change in adults with Down's syndrome. Psychol Med. 1998;28(6):1365-1377.
7. Rowe J, Lavender A, Turk V. Cognitive executive function in Down's syndrome. Br J Clin Psychol. 2006;45(pt 1):5-17.
8. Jackson JF, North ER III, Thomas JG. Clinical diagnosis of Down's syndrome. Clin Genet. 1976;9(5):483-487.
9. Wechsler D. Manual for the Wechsler Adult Intelligence Scale, Third Edition. San Antonio, TX: Psychological Corp; 1997.
10. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery, Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press; 1989.
11. Comalli PE Jr, Wapner S, Werner H. Interference effects of Stroop color-word test in childhood, adulthood, and aging. J Genet Psychol. 1962;100:47-53.
12. Wechsler D. Administration and Scoring Manual for the Wechsler Memory Scale, Third Edition. San Antonio, TX: Psychological Corp; 1997.
13. Meyers J, Meyers K. Rey Complex Figure and Recognition Trial: Professional Manual. Odessa, FL: Psychological Assessment Resources Inc; 1995.
14. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia, PA: Lea & Febiger; 1983.
15. Prasher VP, Farrer MJ, Kessling AM, et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol. 1998;43(3):380-383.
16. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38(1):24-26.
17. Tokuda T, Fukushima T, Ikeda S, et al. Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. Ann Neurol. 1997;41(2):271-273.
18. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864-870.
19. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology. 1999;52(8):1555-1562.
20. de Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006;27(3):394-401.
21. Tapiola T, Soininen H, Pirttila T. CSF tau and Abeta42 levels in patients with Down's syndrome. Neurology. 2001;56(7):979-980.
22. Richards BW. Investigation of 142 mosaic mongols and mosaic parents of mongols: cytogenetic analysis and maternal age at birth. J Ment Defic Res. 1974;18(3):199-208.
23. Rowe IF, Ridler MA, Gibberd FB. Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet. 1989;2(8656):229.
24. Puri BK, Zhang Z, Singh I. SPECT in adult mosaic Down's syndrome with early dementia. Clin Nucl Med. 1994;19(11):989-991.
25. Schapiro MB, Kumar A, White B, Grady CL, Friedland RP, Rapoport SI. Alzheimer's disease (AD) in mosaic/translocation Down's syndrome (Ds) without mental retardation. Neurology. 1989;39(suppl 1):169.
26. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology. 1990;40(11):1698-1707.
27. Heston LL, Mastri AR, Anderson VE, White J. Dementia of the Alzheimer type: clinical genetics, natural history, and associated conditions. Arch Gen Psychiatry. 1981;38(10):1085-1090.
28. Hardy J, Goate A, Owen M, Rossor M. Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet. 1989;2(8665):743.
29. Schupf N, Kapell D, Nightingale B, et al. Specificity of the fivefold increase in AD in mothers of adults with Down syndrome. Neurology. 2001;57(6):979-984.
30. Uchida IA, Freeman VC. Trisomy 21 Down syndrome: parental mosaicism. Hum Genet. 1985;70(3):246-248.